Avidity Biosciences (RNA) Total Current Liabilities: 2019-2025
Historic Total Current Liabilities for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to $169.9 million.
- Avidity Biosciences' Total Current Liabilities rose 86.00% to $169.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $169.9 million, marking a year-over-year increase of 86.00%. This contributed to the annual value of $98.0 million for FY2024, which is 21.49% up from last year.
- As of Q3 2025, Avidity Biosciences' Total Current Liabilities stood at $169.9 million, which was up 25.78% from $135.1 million recorded in Q2 2025.
- Avidity Biosciences' 5-year Total Current Liabilities high stood at $169.9 million for Q3 2025, and its period low was $16.3 million during Q2 2021.
- Over the past 3 years, Avidity Biosciences' median Total Current Liabilities value was $84.2 million (recorded in 2024), while the average stood at $87.4 million.
- Data for Avidity Biosciences' Total Current Liabilities shows a peak YoY skyrocketed of 106.19% (in 2022) over the last 5 years.
- Over the past 5 years, Avidity Biosciences' Total Current Liabilities (Quarterly) stood at $29.7 million in 2021, then skyrocketed by 75.02% to $51.9 million in 2022, then spiked by 55.43% to $80.7 million in 2023, then rose by 21.49% to $98.0 million in 2024, then soared by 86.00% to $169.9 million in 2025.
- Its Total Current Liabilities was $169.9 million in Q3 2025, compared to $135.1 million in Q2 2025 and $84.9 million in Q1 2025.